TIDMAGL
RNS Number : 2317Z
Angle PLC
25 May 2016
ANGLE plc ("the Company")
CANCER RESEARCH UK MANCHESTER INSTITUTE ADOPTS PARSORTIX FOR
ROUTINE USE WITHIN CLINICAL TRIALS PORTFOLIO
Parsortix system already in 10 current clinical trials with a
further 4 clinical trials at planning stage
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is delighted to announce that it has signed a contract with The
University of Manchester, acting in this instance, through the
Cancer Research UK Manchester Institute which will allow
incorporation of ANGLE's Parsortix system in the Clinical and
Experimental Pharmacology group for routine use in clinical trials
and for research purposes.
The contract also provides for the continuation of the Clinical
and Experimental Pharmacology group's work on the development and
validation of new protocols demonstrating the system's utility for
various applications in a variety of cancer types thereby enhancing
the customer offering.
Utilisation of the Parsortix system in clinical drug trials is a
key part of ANGLE's strategy for commercialising Parsortix. Work by
the Clinical and Experimental Pharmacology group to integrate the
Parsortix system into clinical trial work flows will be key to
ensuring wider adoption into a wide range of clinical trials.
As a result of the Clinical and Experimental Pharmacology
group's successful evaluation of pre-clinical samples with the
Parsortix system since 2012 and the strength of the technical and
clinical data generated, Clinical and Experimental Pharmacology is
now routinely using Parsortix as an epitope-independent technology
for circulating tumour cell (CTC) capture and harvest.
The Parsortix system is currently being utilised by Clinical and
Experimental Pharmacology in 10 clinical trials with an additional
4 trials in the planning stage. As a consequence of this inclusion,
over 700 clinical samples have been processed and banked using
established methods developed and published by the Clinical and
Experimental Pharmacology group.
The Clinical and Experimental Pharmacology group believes that
the ability to bank samples following a simple and rapid CTC
enrichment using Parsortix is extremely valuable since it allows
great flexibility for subsequent cellular and molecular analysis of
selected samples. They believe that this approach has the potential
to provide significant clinical insight across a range of cancer
types and will contribute to a hugely valuable dataset.
The Cancer Research UK Manchester Institute is part of the
Manchester Cancer Research Centre (MCRC) which is a partnership
founded by The University of Manchester, The Christie NHS
Foundation Trust and Cancer Research UK. The MCRC brings together
the expertise, ambition and resources of its partner organisations
in the fields of cancer treatment and clinical research and
provides outstanding facilities where researchers and clinicians
can work closely together. The aim of the MCRC is to improve
understanding of how cancer develops, in order to translate basic
and clinical research into new diagnostic tests and treatments that
benefit cancer patients.
The Christie is one of the largest single-site cancer hospitals
in Europe treating more than 44,000 patients per annum. The
hospital has one of the largest clinical trial portfolios in the
UK, with more than 620 active clinical trials over the full range
of adult and teenage cancers. Typically, patients will be
considered for clinical trials where they are no longer responding
to standard therapies. A liquid biopsy using Parsortix has the
potential to determine which clinical trials might be appropriate
for a given patient.
Ged Brady, Deputy and Genomics Leader within the Clinical and
Experimental Pharmacology group at the Cancer Research UK
Manchester Institute, commented:
"Having worked on the development of the Parsortix system over
the last four years, we are now delighted to be incorporating the
Parsortix system into our laboratory for routine use as an
epitope-independent CTC harvesting system applied to clinical
samples. Results so far are encouraging and our ambition is to
evaluate the output from Parsortix sample harvesting to establish
data that can be used to benefit cancer patients."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This contract meets a key milestone for ANGLE to get the
Parsortix system adopted in routine use for clinical trials by the
Cancer Research UK Manchester Institute. This will not only
generate ongoing revenues for the Company but also act as a key
reference for other clinical trial customers."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTGUGDUSXDBGLU
(END) Dow Jones Newswires
May 25, 2016 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024